CENTESSA PHARMACEUTICALS PLC's ticker is CNTA and the CUSIP is 152309100. A total of 81 filers reported holding CENTESSA PHARMACEUTICALS PLC in Q2 2024. The put-call ratio across all filers is 0.25 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,114,853 | -0.6% | 123,461 | -12.3% | 0.01% | -8.3% |
| Q4 2023 | $1,121,214 | -17.6% | 140,856 | -33.0% | 0.01% | -25.0% |
| Q3 2023 | $1,360,020 | -68.1% | 210,204 | -69.4% | 0.02% | -68.0% |
| Q2 2023 | $4,257,253 | +50.2% | 687,763 | -6.6% | 0.05% | +28.2% |
| Q1 2023 | $2,833,573 | +316.6% | 735,993 | +235.4% | 0.04% | +333.3% |
| Q4 2022 | $680,202 | -5.3% | 219,420 | +22.9% | 0.01% | -10.0% |
| Q3 2022 | $718,000 | -88.8% | 178,568 | -86.4% | 0.01% | -89.9% |
| Q2 2022 | $6,402,000 | -19.1% | 1,314,652 | +48.9% | 0.10% | -23.3% |
| Q1 2022 | $7,917,000 | -12.2% | 882,633 | +10.2% | 0.13% | 0.0% |
| Q4 2021 | $9,021,000 | -38.8% | 801,136 | -9.3% | 0.13% | -46.5% |
| Q3 2021 | $14,743,000 | -19.3% | 882,813 | +7.3% | 0.24% | -29.3% |
| Q2 2021 | $18,268,000 | – | 822,518 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Index Venture Life Associates VI Ltd | 9,961,789 | $89,357,000 | 100.00% |
| Medicxi Ventures Management (Jersey) Ltd | 19,963,157 | $179,070,000 | 48.51% |
| Vida Ventures Advisors, LLC | 3,931,818 | $35,268,000 | 20.51% |
| OUP Management Co., LLC | 2,937,615 | $26,350,000 | 20.06% |
| Samsara BioCapital, LLC | 1,884,096 | $16,900,000 | 4.26% |
| Kynam Capital Management, LP | 669,100 | $6,002,000 | 1.95% |
| Cormorant Asset Management, LP | 2,489,894 | $22,334,000 | 1.72% |
| GENERAL ATLANTIC, L.P. | 9,681,818 | $86,846,000 | 0.79% |
| RA Capital Management | 3,577,094 | $32,087,000 | 0.70% |
| BVF INC/IL | 1,755,545 | $15,747,000 | 0.63% |